Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs.
Flawless balance sheet with acceptable track record.
Share Price & News
How has Xencor's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: XE9's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: XE9 exceeded the German Biotechs industry which returned 3.7% over the past year.
Return vs Market: XE9 exceeded the German Market which returned 6.1% over the past year.
Price Volatility Vs. Market
How volatile is Xencor's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Xencor undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: XE9 (€29.8) is trading above our estimate of fair value (€21.49)
Significantly Below Fair Value: XE9 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: XE9 is poor value based on its PE Ratio (67.5x) compared to the Biotechs industry average (37.5x).
PE vs Market: XE9 is poor value based on its PE Ratio (67.5x) compared to the German market (20.2x).
Price to Earnings Growth Ratio
PEG Ratio: XE9's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: XE9 is good value based on its PB Ratio (3.1x) compared to the DE Biotechs industry average (3.2x).
How is Xencor forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XE9's earnings are forecast to decline over the next 3 years (-11.8% per year).
Earnings vs Market: XE9's earnings are forecast to decline over the next 3 years (-11.8% per year).
High Growth Earnings: XE9's earnings are forecast to decline over the next 3 years.
Revenue vs Market: XE9's revenue (23.8% per year) is forecast to grow faster than the German market (5.1% per year).
High Growth Revenue: XE9's revenue (23.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if XE9's Return on Equity is forecast to be high in 3 years time
How has Xencor performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: XE9 has high quality earnings.
Growing Profit Margin: XE9 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: XE9 has become profitable over the past 5 years, growing earnings by 7.8% per year.
Accelerating Growth: XE9 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: XE9 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: XE9's Return on Equity (4.5%) is considered low.
Return on Assets
Return on Capital Employed
How is Xencor's financial position?
Financial Position Analysis
Short Term Liabilities: XE9's short term assets ($558.4M) exceed its short term liabilities ($66.6M).
Long Term Liabilities: XE9's short term assets ($558.4M) exceed its long term liabilities ($10.5M).
Debt to Equity History and Analysis
Debt Level: XE9 is debt free.
Reducing Debt: XE9 had no debt 5 years ago.
Debt Coverage: XE9 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: XE9 has no debt, therefore coverage of interest payments is not a concern.
Inventory Level: XE9 has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if XE9's debt is covered by short term assets.
What is Xencor's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate XE9's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate XE9's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if XE9's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if XE9's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of XE9's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bassil Dahiyat (49yo)
Dr. Bassil I. Dahiyat, Ph.D. Co-founded Xencor, Inc. in August 1997 and has been its President and Chief Executive Officer since February 2005. Dr. Dahiyat served as Chief Executive Officer of Xencor from ...
CEO Compensation Analysis
Compensation vs Market: Bassil's total compensation ($USD4.37M) is above average for companies of similar size in the German market ($USD1.63M).
Compensation vs Earnings: Bassil's compensation has been consistent with company performance over the past year.
|Senior VP of Finance & CFO||9.3yrs||US$1.86m||0.13% $2.3m|
|Senior VP of Research & Chief Scientific Officer||5.6yrs||US$1.92m||0.15% $2.6m|
|Associate Director and Head of Corporate Communications & Investor Relations||0yrs||no data||no data|
|VP, General Counsel & Corporate Secretary||0.4yrs||no data||no data|
|Senior VP & Chief Medical Officer||0.2yrs||no data||no data|
Experienced Management: XE9's management team is seasoned and experienced (5.6 years average tenure).
|Independent Director||2.2yrs||US$232.87k||no data|
|Member of Scientific Advisory Board||0yrs||no data||no data|
|Independent Director||4.9yrs||US$273.66k||no data|
|Independent Director||4.6yrs||US$235.13k||no data|
|Independent Director||2.8yrs||US$231.38k||no data|
|Member of Scientific Advisory Board||10.7yrs||no data||no data|
|Independent Director||1.3yrs||US$409.76k||no data|
|Independent Director||5.6yrs||US$240.13k||no data|
|Director||0.2yrs||no data||no data|
Experienced Board: XE9's board of directors are considered experienced (4.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.8%.
Xencor, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Xencor, Inc.
- Ticker: XE9
- Exchange: DB
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.890b
- Listing Market Cap: US$1.737b
- Shares outstanding: 56.72m
- Website: https://www.xencor.com
Number of Employees
- Xencor, Inc.
- 111 West Lemon Avenue
- 2nd Floor
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|XNCR||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Dec 2013|
|XE9||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Dec 2013|
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company’s product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for the treatment of asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers MOR208, an antibody drug that is in Phase III clinical trial to treat non-Hodgkin lymphomas, as well as in Phase II clinical trial for chronic lymphocytic leukemia; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG50, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, XmAb23104, and XmAb24306 which are in preclinical Phase. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; MorphoSys Ag; Amgen Inc.; and Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/25 22:52|
|End of Day Share Price||2020/02/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.